Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
To Purchase # 5216SC
|5216SC||10 µg (With Carrier)||$199.00|
|5216SF||10 µg (Carrier Free)||$199.00|
|5216LC||50 µg (With Carrier)||$599.00|
|5216LF||50 µg (Carrier Free)||$599.00|
|$ 0. 00|
Find answers on our FAQs page.
PTM information and tools available.
Mouse Interleukin-6 (mIL-6) #5216
The purity of recombinant mIL-6 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-6 and staining overnight with Coomassie Blue.Learn more about how we get our images
The proliferation of B9 cells treated with increasing concentrations of mIL-6 was assessed. After 48 hour treatment with mIL-6, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.Learn more about how we get our images
Gallery: Mouse Interleukin-6 (mIL-6) #5216
- The purity of recombinant mIL-6 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-6 and staining overnight with Coomassie Blue.
- The proliferation of B9 cells treated with increasing concentrations of mIL-6 was assessed. After 48 hour treatment with mIL-6, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
- Western blot analysis of extracts from B9 cells, untreated or treated with increasing concentrations of mIL-6 for 10 minutes, using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper) and Stat3 (79D7) Rabbit mAb #4904 (lower).
Recombinant mouse IL-6 (mIL-6) Phe25-Thr211 (Accession #NP_112445) was expressed in human 293 cells at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-6. All lots are greater than 98% pure.Molecular Formula:
Recombinant mIL-6 contains no "tags" and the nonglycosylated protein has a calculated MW of 21,734. DTT-reduced and non-reduced protein migrate as 31 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation. The expected amino-terminal FPTSQ of recombinant mIL-6 was verified by amino acid sequencing.Bioactivity:
The bioactivity of recombinant mIL-6 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 and 2 pg/ml.Endotoxin:
Less than 0.01 ng endotoxin/1 μg mIL-6.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial, and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, and others. IL-6 in concert with TGFβ is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/MAPK (Erk) cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3).The IL-6/soluble IL-6Rα complex can then activate the gp130 signaling pathway on cells that express gp130 but not IL-6Rα (3). IL-6, through increasing expression of proangiogenic VEGF, may contribute to metastatic breast cancer (5).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.